Alex Brill Interviewed by Biosimilars Review & Report
Following the release of the new MGA white paper “The Long-Term Effects of Medicare Price Negotiations on Drug Competition,” Alex Brill spoke with Stanton Mehr at Biosimilars Review & Report. Describing the concept of the MGA white paper, Alex explained, “We believe that the government’s price negotiations program will substitute for some degree of biosimilar competition that would otherwise occur. It will have a chilling effect on biosimilar development by reducing or eliminating the profit opportunities that will exist for biosimilar manufacturers down the road. That will discourage biosimilar firms from taking the risk.”
Click here to read the full interview.
